Chagas disease, caused by the protozoan Trypanosoma cruzi, is recognized as a serious public health problem in Brazil and worldwide. The availability of drugs for Chagas' disease is extremely restrict and therefore it is estimated that only 1% of infected individuals receiving some type of treatment. Many natural and synthetic products have being evaluated against Trypanosoma cruzi, such as the synthetic derivative of gallic acid, tetradecil gallate, which is used in this project. To solve the problems of the compound solubility in water and consequently improve its bioavailability, lipid carriers will be used in controlled systems, to obtain release rates and appropriate activity of the drug in the body. In this context, this project aims at the synthesis and characterization of lipid nanocarriers to encapsulate the compound galato de tetradecila. Furthermore, will be performed continuous electrochemical in vitro monitoring of the kinetics of drug release from therapeutic nanoparticles. For this purpose an electrochemical sensor is used as analytical method for the detection of low levels of analyte concentration in solution. The electrochemical protocol for real-time monitoring will be able to evaluate the release profile an essential factor to establish therapeutic index of the drug and the potential clinical appliance.
News published in Agência FAPESP Newsletter about the scholarship: